The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia

International Journal of Geriatric Psychiatry

Volumn 18, Issue 5, 2003, Pages 432-440

  Ritchie, C W ^a   Chiu, E ^b   Harrigan, S ^b   Hall, K ^c   Hassett, A ^b   MacFarlane, S ^b   Mastwyk, M ^b   O'Connor, D W ^c   Opie, J ^c   Ames, D ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Elderly; Extra pyramidal side effects; Olanzapine; Quality of life; Risperidone; Schizophrenia; Switching

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT FAILURE; URINARY HESITANCY; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHOMOTOR DISORDERS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA;

EID: 0038135026     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.862     Document Type: Article

References (26)

1. Andreasen NC. 1989. The scale for the assessment of negative symptoms (SANS): Conceptual and theoretical foundations. Br J Psychiatry 155: S49-S52.
2. Barak Y, Zemishlani C, Mirecki I, et al. 2001. Olanzapine versus haloperidol for elderly schizophrenia patients. In Abstracts of the 10th Congress of the International Psychogeriatric Association; September 9-14, 2001; Nice, France; Abstract P-169.
3. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Berman I, Merson A, Rachov-Pavlov J, et al. 1996. Risperidone in elderly schizophrenic patients. Am J Geriatric Psychiatry 4(2): 173-178.
5. Davidson M, Harvey PD, Vervacke J, et al. 2000. A long-term, multicentre, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 15(6): 506-514.
6. Geddes J, Freemantle N, Harrison P, Bebbington P. 2000. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression. BMJ 321: 1371-1376.
7. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 12: 189-198.
8. Jeste DV, Caligiuri MP, Paulsen JS, et al. 1995. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients. Arch Gen Psychiatry 52: 756-765.
9. Jeste DV, Rockwell E, Harris MJ, et al. 1999. Conventional versus newer antipsychotics in elderly. Am J Geriatric Psychiatry 7: 70-76.
10. Jeste D, Madhusoodanan S, Barak Y, et al. 2001. Risperidone and olanzapine in elderly patients with schizophrenia and schizoaffective disorder. In Abstracts of the 10th Congress of the International Psychogeriatric Association; September 9-14, 2001; Nice, France; Abstract P-358.
11. Joshi PM, Joshi U. 1996. Risperidone in treatment-resistant geriatric patients with chronic psychosis and concurrent medical illnesses. In Abstracts of the 149th Annual Meeting of the American Psychiatric Association, New York, USA May 4-9; Abstract NR337.
12. Kiraly SJ, Gibson RE, Ancill RJ, Holliday SG. 1998. Risperidone: Treatment response in adult and geriatric patients. Int J Psychiatry Med 28(2): 255-263.
13. Maguire G, Kennedy J, Shaw SC, et al. 2001. Acute double blind comparison of olanzapine and haloperidol in schizophrenia patients age over 60. In Abstracts of the 10th Congress of the International Psychogeriatric Association; September 9-14, 2001; Nice, France; Abstract P-168.
14. Madhusoodanan S, Brenner R, Araujo L, Abaza A. 1995. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case series. J Clin Psychiatry 56: 514-618.
15. Madhusoodanan S, Suresh P, Brenner R, Pillai R. 1999a. Experience with the atypical antipsychotics risperidone and olanzapine in the elderly. Ann Clin Psychiatry 11(3): 113-118.
16. Madhusoodanan S, Brenner R, Kascow JW, et al. 1999b. Risperidone in elderly patients with psychotic disorders. In New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 18, 1997; Abstract NR601:230 San Diego.
17. Madhusoodanan S, Brenner R, Suresh P, et al. 2000. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: A prospective study. Ann Clin Psychiatry 12(1): 11-18.
18. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
19. National Institute of Mental Health. 1975. Abnormal involuntary movement scale. Early Clin Drug Eval Unit Intercom 4: 3-6.
20. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psycholog Rep 10: 799-812.
21. Schooler N, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-487.
22. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(Suppl.): 11-19.
23. Solomons K, Geiger O. 2000. Olanzapine use in the elderly: A retrospective analysis. Can J Psychiatry 45(2): 151-155.
24. Sweet RA, Pollock BG. 1995. Neuroleptics in the elderly: Guidelines for monitoring. Harvard Rev Psychiatry 2: 327-335.
25. Wirshing DA, Spellberg BJ, Lanzio M, et al. 1998. Novel antipsychotics and new onset diabetes. Biol Psychiatry 44: 778-783.
26. World Health Organization. 1996. WHOQOL-BREF Introduction, Administration, Scoring and Generic Version of the Assessment. WHO: Geneva.